April 24 | 2019
Notice of annual general meeting in 2cureX AB (publ)
Read more
April 24 | 2019
2cureX decides on rights issue prior to market launch of IndiTreat®
Read more
April 4 | 2019
2cureX announces commercial collaboration with Gibson Oncology, USA
Read more
April 2 | 2019
Communique from extraordinary general meeting of 2cureX AB (publ)
Read more
March 28 | 2019
2cureX receives Notice of Allowance from the United States Patent Office
Read more
March 14 | 2019
Notice of extraordinary general meeting in 2cureX AB (publ)
Read more
March 12 | 2019
2cureX expands its activities to preventive cancer medicine
Read more
March 1 | 2019
2cureX publishes year-end report for the fiscal year 2018
Read more
February 20 | 2019
Correction – Lack of reference to MAR – 2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients
Read more
February 20 | 2019
2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients
Read more
February 1 | 2019
2cureX gathered decision makers at New Year’s Reception
Read more
January 16 | 2019
2cureX strengthens the organisation via the recruitment of a CFO
Read more
December 10 | 2018
2cureX is accelerating the launch of IndiTreat®
Read more
November 23 | 2018
2cureX AB publishes interim report for January – September 2018
Read more
November 16 | 2018
The University Hospital, Vejle Hospital and 2cureX have received approval to start a clinical trial in pancreatic cancer
Read more
October 23 | 2018
Poster presentation at ESMO 2018 in Munich
Read more
October 18 | 2018
Article from BioStock
Read more
October 9 | 2018
2cureX announces CE-IVD marking of its IndiTreat test
Read more